Legend Biotech has a best-in-class product and could become a global leader in the cell and gene therapy space, according to Goldman Sachs.
"We believe Legend has the potential to grow into a leading global cell therapy company," Chen said in a note to clients.
Its leading therapy in the space is Carvykti, which he described as "best-in-class."
In partnership with Johnson & Johnson , Carvykti is undergoing capacity expansion in the U.S. and European Union to meet demand.
Legend stock rose 0.3% in Monday's session.
Persons:
Goldman Sachs, Ziyi Chen, Chen, Johnson, Carvykti, — CNBC's Michael Bloom
Organizations:
Biotech, Johnson, Union
Locations:
U.S